Adenoid Cystic Carcinoma Market to Grow Positively at a Paltry CAGR During the Study Period (2019-2032) | Merck, Ayala Pharmaceuticals, and others

DelveInsight's "Adenoid Cystic Carcinoma - Market Insight, Epidemiology and Market Forecast - 2032" report provides current treatment practices, emerging drugs, Adenoid Cystic Carcinoma market share of the individual therapies, current and forecasted Adenoid Cystic Carcinoma market size from 2019 to 2032 segmented by seven major markets. The report also offers current Adenoid Cystic Carcinoma therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Adenoid Cystic Carcinoma market.

Download a sample report: https://www.delveinsight.com/report-store/adenoid-cystic-carcinoma-acc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Highlights from the adenoid cystic carcinoma market report:

According to Calderón Boyle et al. (2020) in the US, Adenoid Cystic Carcinoma incidence rate was 0.35 per 100,000. Adenoid Cystic Carcinoma limited duration prevalence was highest in those aged 75-79 years and in females, and lowest among Native Americans/Alaska Natives. Adenoid Cystic Carcinoma cases were highest in the oral cavity and pharynx.
A multicenter Baujat et al. (2020), the across Europe average age for Adenoid Cystic Carcinoma was 55 years and females accounted for 59.4% of the cohort. The body mass index (BMI) was normal in 86% of cases while tumor was located in minor salivary glands in 60% of cases. T3/T4 stages represented 58%; 89% of patients and histological grade III was observed on 21% of patients. The EFS and overall 5-year survival rates were 50% and 85%, respectively.
According to Inagaki et al. (2020) study of Adenoid Cystic Carcinoma cases of salivary gland origin in Japan, 5-year overall survival (OS) and disease-free survival (DFS) rates were 92.5% and 50.0%, respectively with treatment failure in 46% cases while distant failures in 34%.
Adenoid Cystic Carcinoma Market Companies are working in the market such as Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck & Co, and others.
Adenoid Cystic Carcinoma epidemiology is segmented as Total Adenoid Cystic Carcinoma Incident Cases, Adenoid Cystic Carcinoma Gender-specific Cases, Adenoid Cystic Carcinoma Grade-specific Cases, and Adenoid Cystic Carcinoma Treatable Cases in the Adenoid Cystic Carcinoma market report.

Adenoid Cystic Carcinoma Overview
Adenoid cystic carcinoma (ACC) is an uncommon type of adenocarcinoma that originates in glandular tissues. It primarily occurs in the salivary glands or other areas of the head and neck but can also appear in various other locations, such as the breast, skin, cervix in women, and prostate gland in men. ACC tumors are distinguished by a unique histological pattern featuring abnormal "nests" or cords of epithelial cells that either surround or invade ducts or glandular structures within the affected organ. These structures are typically filled with mucous-like material or contain abnormal fibrous membranes, visible under microscopic examination.

Signs & Symptoms: The symptoms of ACC vary depending on its location. Early-stage salivary gland tumors usually present as painless, slowly growing masses in the mouth or face. Advanced tumors may cause pain and nerve paralysis. Tumors in the lacrimal gland can lead to proptosis and vision changes, while those in the tracheobronchial tree may result in respiratory issues. ACC affecting the larynx can lead to voice changes.

Diagnosis: ACC is diagnosed through histological analysis of a biopsy or tumor specimen. There are no specific serum markers for this cancer. Recurrences are typically detected using imaging techniques such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans. ACC can exhibit three common growth patterns: cribriform, tubular, and solid. The cribriform pattern is the most common, with cribriform and tubular patterns generally being less aggressive. The World Health Organization (WHO) classifies ACC into Grade I, II, and III based on these patterns.

Causes: The precise cause of ACC is not known, but researchers suggest that a protein produced by the MYB-NFIB fusion gene may contribute to its development. ACC shows a slight female predominance and is staged using the TNM system for salivary gland tumors.

Treatment: The primary treatment for ACC is surgical resection, often followed by postoperative radiotherapy. Neutron beam therapy may offer advantages over conventional radiation in reducing local recurrence. ACC is generally resistant to chemotherapy, though some patients may receive palliative care. Ongoing clinical trials are evaluating new chemotherapeutic agents, such as paclitaxel and gemcitabine, either alone or in combination, for managing metastatic or locally recurrent ACC.

Prognosis: ACC is a low-grade malignancy with slow growth. While it rarely invades nearby lymph nodes or perineural spaces, it has a tendency for local recurrence. Approximately half of the patients experience distant metastasis, particularly to the lungs, leading to serious complications. Despite this, many ACC patients survive for five years or more, though recurrence and progression of tumors are common.
To know more about adenoid cystic carcinoma in detail, visit: https://www.delveinsight.com/report-store/adenoid-cystic-carcinoma-acc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Adenoid Cystic Carcinoma Epidemiological Insights
According to Calderón Boyle et al. (2020) in the US, Adenoid Cystic Carcinoma incidence rate was 0.35 per 100,000. Adenoid Cystic Carcinoma limited duration prevalence was highest in those aged 75-79 years and in females, and lowest among Native Americans/Alaska Natives. Adenoid Cystic Carcinoma cases were highest in the oral cavity and pharynx.
A multicenter Baujat et al. (2020), the across Europe average age for Adenoid Cystic Carcinoma was 55 years and females accounted for 59.4% of the cohort. The body mass index (BMI) was normal in 86% of cases while tumor was located in minor salivary glands in 60% of cases. T3/T4 stages represented 58%; 89% of patients and histological grade III was observed on 21% of patients. The EFS and overall 5-year survival rates were 50% and 85%, respectively.
According to Inagaki et al. (2020) study of Adenoid Cystic Carcinoma cases of salivary gland origin in Japan, 5-year overall survival (OS) and disease-free survival (DFS) rates were 92.5% and 50.0%, respectively with treatment failure in 46% cases while distant failures in 34%.
The disease epidemiology covered in the report provides historical as well as forecasted Adenoid Cystic Carcinoma epidemiology [segmented as Total Incident Cases of Adenoid Cystic Carcinoma, Gender-specific Cases of Adenoid Cystic Carcinoma, Grade-specific Cases of Adenoid Cystic Carcinoma, and Treatable Cases of Adenoid Cystic Carcinoma] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Adenoid Cystic Carcinoma Market Outlook
Surgical resection is the primary treatment for Adenoid Cystic Carcinoma (ACC), although it may be associated with complications that vary depending on the surgical site. For instance, surgery on the parotid salivary gland can damage facial nerves, leading to muscle drooping in the face. Based on clinical trial experience, many experts also recommend postoperative radiotherapy as an adjuvant therapy to help reduce local failure. In some cases, surgical removal of ACC may not be feasible.

When initial surgery is not an option due to the location or progression of the malignancy, radiation therapy may be employed. The type of radiation used depends on various factors such as the cancer type, location, stage, grade, and prior treatments. Thermal ablation is another commonly used alternative for patients with metastases.

Systemic therapies play a limited role in the treatment of ACC, as this cancer does not typically respond well to chemotherapy. Chemotherapy is sometimes used as a palliative measure. Targeted therapies, such as tyrosine kinase inhibitors (TKIs) like lenvatinib or sorafenib, have shown promise but are still in developmental phases and require further research to establish their efficacy.

The dynamics of the ACC market are expected to change in the coming years due to increasing awareness and improvements in research and development. Key companies in the ACC market, such as Merck and Ayala Pharmaceuticals, are involved in developing new therapies for this cancer.

Promising Therapies in the Adenoid Cystic Carcinoma Pipeline
lenvatinib and pembrolizumab
AL101
And others
Discover more about Adenoid Cystic Carcinoma therapies in the pipeline @ https://www.delveinsight.com/sample-request/adenoid-cystic-carcinoma-acc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Adenoid Cystic Carcinoma Market
Merck
Ayala Pharmaceuticals
And others
To understand key companies related to the Adenoid Cystic Carcinoma Market, get a snapshot of the Adenoid Cystic Carcinoma Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/adenoid-cystic-carcinoma-acc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Adenoid Cystic Carcinoma Market Report
Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Adenoid Cystic Carcinoma Companies: Merck, Ayala Pharmaceuticals, and others
Key Adenoid Cystic Carcinoma Pipeline Therapies: AD04 (ondansetron), MN-166 (ibudilast), CORT118335 (mifepristone), and others
Therapeutic Assessment: Adenoid Cystic Carcinoma current marketed and emerging therapies
Adenoid Cystic Carcinoma Market Dynamics: Adenoid Cystic Carcinoma market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Adenoid Cystic Carcinoma Market Access and Reimbursement
Table of Contents
1. Adenoid Cystic Carcinoma Market Key Insights
2. Adenoid Cystic Carcinoma Market Report Introduction
3. Adenoid Cystic Carcinoma Market Overview at a Glance
4. Adenoid Cystic Carcinoma Market Executive Summary
5. Disease Background and Overview
6. Adenoid Cystic Carcinoma Treatment and Management
7. Adenoid Cystic Carcinoma Epidemiology and Patient Population
8. Patient Journey
9. Adenoid Cystic Carcinoma Emerging Drugs
10. 7MM Adenoid Cystic Carcinoma Market Analysis
11. Adenoid Cystic Carcinoma Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Adenoid Cystic Carcinoma Market Drivers
15. Adenoid Cystic Carcinoma Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports by DelveInsight:

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.